Terms: = Small Cell Lung Cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Clinical Outcome
35 results:
1. Prognostic impact of age in advanced non-small cell lung cancer patients undergoing first-line checkpoint inhibitor immunotherapy and chemotherapy treatment.
Huang X; Wu S; Chen S; Qiu M; Zhao Y; Wei J; He J; Zhao W; Tan L; Su C; Zhou S
Int Immunopharmacol; 2024 May; 132():111901. PubMed ID: 38554448
[TBL] [Abstract] [Full Text] [Related]
2. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Negrao MV; Araujo HA; Lamberti G; Cooper AJ; Akhave NS; Zhou T; Delasos L; Hicks JK; Aldea M; Minuti G; Hines J; Aredo JV; Dennis MJ; Chakrabarti T; Scott SC; Bironzo P; Scheffler M; Christopoulos P; Stenzinger A; Riess JW; Kim SY; Goldberg SB; Li M; Wang Q; Qing Y; Ni Y; Do MT; Lee R; Ricciuti B; Alessi JV; Wang J; Resuli B; Landi L; Tseng SC; Nishino M; Digumarthy SR; Rinsurongkawong W; Rinsurongkawong V; Vaporciyan AA; Blumenschein GR; Zhang J; Owen DH; Blakely CM; Mountzios G; Shu CA; Bestvina CM; Garassino MC; Marrone KA; Gray JE; Patel SP; Cummings AL; Wakelee HA; Wolf J; Scagliotti GV; Cappuzzo F; Barlesi F; Patil PD; Drusbosky L; Gibbons DL; Meric-Bernstam F; Lee JJ; Heymach JV; Hong DS; Heist RS; Awad MM; Skoulidis F
Cancer Discov; 2023 Jul; 13(7):1556-1571. PubMed ID: 37068173
[TBL] [Abstract] [Full Text] [Related]
3. Genetic variants in LKB1/AMPK/mTOR pathway are associated with clinical outcomes of chemotherapy in non-small cell lung cancer.
Choi SH; Do SK; Lee SY; Choi JE; Kang HG; Hong MJ; Lee JH; Lee WK; Jeong JY; Shin KM; Do YW; Lee EB; Park JE; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
Thorac Cancer; 2022 Dec; 13(23):3322-3330. PubMed ID: 36239337
[TBL] [Abstract] [Full Text] [Related]
4. Relationship between the microRNAs and PI3K/akt/mTOR axis: Focus on non-small cell lung cancer.
Lin Y; Zhang L; Ding X; Chen C; Meng M; Ke Y; Wang W
Pathol Res Pract; 2022 Nov; 239():154093. PubMed ID: 36183437
[TBL] [Abstract] [Full Text] [Related]
5. Mutations and clinical significance of calcium voltage-gated channel subunit alpha 1E (CACNA1E) in non-small cell lung cancer.
Gao SH; Wang GZ; Wang LP; Feng L; Zhou YC; Yu XJ; Liang F; Yang FY; Wang Z; Sun BB; Wang D; Liang LJ; Xie DW; Zhao S; Feng HP; Li X; Li KK; Tang TS; Huang YC; Wang SQ; Zhou GB
Cell Calcium; 2022 Mar; 102():102527. PubMed ID: 35026540
[TBL] [Abstract] [Full Text] [Related]
6. ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer.
Reissig TM; Sara L; Ting S; Reis H; Metzenmacher M; Eberhardt WEE; Zaun G; Herold T; Aigner C; Darwiche K; Stuschke M; Schildhaus HU; Schuler M; Wiesweg M
Lung Cancer; 2020 Nov; 149():10-16. PubMed ID: 32947221
[TBL] [Abstract] [Full Text] [Related]
7. Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma.
Krencz I; Sebestyen A; Papay J; Lou Y; Lutz GF; Majewicz TL; Khoor A
Hum Pathol; 2019 Nov; 93():74-80. PubMed ID: 31454632
[TBL] [Abstract] [Full Text] [Related]
8. Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients.
Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Cabeza Barrera J; Faus-Dáder MJ
Mutat Res Rev Mutat Res; 2019; 781():63-70. PubMed ID: 31416579
[TBL] [Abstract] [Full Text] [Related]
9. Carcinogen-induced tumors in SFN-transgenic mice harbor a characteristic mutation spectrum of human lung adenocarcinoma.
Kim Y; Shiba-Ishii A; Ramirez K; Muratani M; Sakamoto N; Iijima T; Noguchi M
Cancer Sci; 2019 Aug; 110(8):2431-2441. PubMed ID: 31144406
[TBL] [Abstract] [Full Text] [Related]
10. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/akt/MYC pathway.
Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
[TBL] [Abstract] [Full Text] [Related]
11. The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
Oh YJ; Park SY; Seo YH
Oncol Rep; 2018 Apr; 39(4):1775-1782. PubMed ID: 29436674
[TBL] [Abstract] [Full Text] [Related]
12. Cyclin-dependent kinase 5 controls vasculogenic mimicry formation in non-small cell lung cancer via the FAK-akt signaling pathway.
Zhou X; Gu R; Han X; Wu G; Liu J
Biochem Biophys Res Commun; 2017 Oct; 492(3):447-452. PubMed ID: 28842255
[TBL] [Abstract] [Full Text] [Related]
13. Alex3 suppresses non-small cell lung cancer invasion via akt/Slug/E-cadherin pathway.
Du J; Zhang X; Zhou H; Miao Y; Han Y; Han Q; Wang E
Tumour Biol; 2017 Jul; 39(7):1010428317701441. PubMed ID: 28705116
[TBL] [Abstract] [Full Text] [Related]
14. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
[TBL] [Abstract] [Full Text] [Related]
15. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.
Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Robles AI; Faus-Dáder MJ; Calleja-Hernández MÁ
Mutat Res Rev Mutat Res; 2017; 771():32-58. PubMed ID: 28342452
[TBL] [Abstract] [Full Text] [Related]
16. cancer cells increase endothelial cell tube formation and survival by activating the PI3K/akt signalling pathway.
Cheng HW; Chen YF; Wong JM; Weng CW; Chen HY; Yu SL; Chen HW; Yuan A; Chen JJ
J Exp Clin Cancer Res; 2017 Feb; 36(1):27. PubMed ID: 28173828
[TBL] [Abstract] [Full Text] [Related]
17. Polymorphisms in epidermal growth factor receptor (EGFR) and akt1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Zhang X; Fan J; Li Y; Lin S; Shu P; Ni J; Qin S; Zhang Z
Tumour Biol; 2016 Jan; 37(1):1061-9. PubMed ID: 26269114
[TBL] [Abstract] [Full Text] [Related]
18. High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients.
Tsai JR; Wang HM; Liu PL; Chen YH; Yang MC; Chou SH; Cheng YJ; Yin WH; Hwang JJ; Chong IW
Cell Oncol (Dordr); 2012 Dec; 35(6):461-71. PubMed ID: 23055342
[TBL] [Abstract] [Full Text] [Related]
19. Genetic variants in the PI3K/PTEN/akt/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
[TBL] [Abstract] [Full Text] [Related]
20. Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.
Reungwetwattana T; Molina JR; Mandrekar SJ; Allen-Ziegler K; Rowland KM; Reuter NF; Luyun RF; Dy GK; Marks RS; Schild SE; Jett JR; Adjei AA
J Thorac Oncol; 2012 May; 7(5):919-22. PubMed ID: 22722792
[TBL] [Abstract] [Full Text] [Related]
[Next]
